Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned a consensus rating of “Buy” from the nine analysts that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $15.72.

Several research analysts have commented on the company. Citigroup began coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, March 3rd. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald began coverage on Voyager Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $5.73 target price on the stock.

Voyager Therapeutics Stock Up 2.9 %

VYGR opened at $4.26 on Friday. The firm has a market cap of $232.71 million, a price-to-earnings ratio of 6.00 and a beta of 0.99. Voyager Therapeutics has a 52 week low of $3.80 and a 52 week high of $10.66. The business’s 50 day moving average is $5.01 and its two-hundred day moving average is $5.92.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 10,778 shares of company stock worth $58,548 over the last three months. 4.53% of the stock is currently owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new stake in Voyager Therapeutics during the fourth quarter worth $29,000. Tower Research Capital LLC TRC boosted its position in Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management boosted its position in Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares in the last quarter. Oxford Asset Management LLP purchased a new stake in Voyager Therapeutics during the fourth quarter worth $60,000. Finally, Intech Investment Management LLC purchased a new stake in Voyager Therapeutics during the third quarter worth $74,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.